Why the study?
Is the ACE gene insertion/deletion polymorphism associated with insulin resistance in patients with angina pectoris?
Is the ACE gene insertion/deletion polymorphism associated with insulin resistance in patients with angina pectoris?
The ACE-II genotype is associated with a significantly higher risk of insulin resistance compared to ID and DD genotypes in non-diabetic patients with angina pectoris.
Answers are grounded in this paper and cite their sources.
II genotype associated with insulin resistance in angina; hypothesis-generating for genetic risk stratification, prospective validation needed.
The association between insertion/deletion polymorphism of the angiotensin I converting enzyme (ACE) gene and insulin resistance (IR) was investigated in 64 consecutive patients (F/M: 11/53) with angina pectoris without clinically manifest diabetes mellitus who underwent diagnostic coronary angiography. The observed frequency distribution of ACE genotypes did not deviate from that predicted from the Hardy-Weinberg equilibrium in this group. Patients with the ACE-ID genotype had significantly lower IR, as assessed by an oral glucose tolerance test (OGTT) and by homeostatic model assessment (HOMA), compared to those with the ACE-II genotype, as assessed by a multiple comparison analysis. Patients were divided into two groups with low and high HOMA-IR, and the I allele was seen more frequently in the high HOMA-IR group than in the low HOMA-IR group (0.62 v 0.47, respectively, by chi2 test, P < .05). Logistic regression analysis showed that the odds ratio for insulin resistance in patients with the II genotype, compared to those with the ID and DD-genotypes (assuming that the I allele has a recessive effect), was 4.0 (95% confidence interval, 1.2 to 16.5; P = .037), after adjusting for the presence of significant coronary atherosclerosis. In conclusion, the D allele was not associated with higher insulin resistance in patients with angina pectoris; that is, patients with the ID and DD genotypes were associated with a significantly lower risk of insulin resistance, compared to those with the II genotype.
No takes yet. Share an insight, caveat, or question.
Takanobu Takezako (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: